FDA Draft Guidance: Coalition Submits Formal Comment
Coalition submits formal comment on FDA Draft Guidance on “Presenting Risk Information in Prescription Drug and Medical Device Promotion”.
The coalition’s comment, which commends the draft’s many strong points, also criticizes what they believe is the FDA’s over complication of advertising and promotion.
Coalition Asks Senate to Focus on Patient Access to Care
Coalition tells Senate committee that real patient interests trump potential “conflicts of interest” as nation expands access to care.
DTC and Medical Marketing — Tax Issues
From DTC Perspectives:
Representatives John Fleming and Frank Pallone set Erin Burnett of CNBC straight on the value of DTC and why removing its tax deductibility is not a good idea.
The DTC Fight Is Far From Over
Washington lobbyists working with the Advertising Coalition breathed a bit easier Friday when learning that the Ad Tax Provision was not likely to be in the House revenue options for funding healthcare reform. But watch the news carefully.
Read more
Advocates Sound the Alarm Over Congress’s Threats to Tax Drug Advertising
The Advertising Coalition and the AAAA D.C. office report that elimination of the tax deduction for marketing costs for drug and related businesses is still among the revenue options to pay for healthcare reform (HCR).
Read more
FDA Draft Guidance: Potentially a Significant Danger
The Coalition has developed an aggressive plan to address the FDA’s recent “draft guidance” for including risk information in advertising and other marketing materials.
Under the leadership of Harry Sweeney, the Coalition has developed an aggressive plan to address the FDA’s recent “draft guidance” for presenting risk information in advertising and other marketing materials.
Read more
Coalition Defends Use of Rx Data
Read the Coalition’s Amici Brief, submitted to appeals court, defending marketing use of prescription data and asserting First Amendment rights.
4A’s Urges President and Congress to End Efforts to Remove Drug Ad Deductibility
The American Association of Advertising Agencies, along with other members of The Advertising Coalition, are aggressively opposing all efforts to restrict the deductibility of prescription drug advertisements. The deductibility proposal, which has been discussed in Congress and at The White House, is an area of a new revenue package being considered as part of a new healthcare reform.
The Advertising Coalition, of which the 4A’s is a founding member, is coordinating the industry’s efforts to defeat any changes to the deductibility rules. The broad coalition comprises marketers, clients and media outlets.
Download the Letter Sent by The Advertising Coalition to President Obama
“This is a very real and an extremely serious threat,” said Dick O’Brien, head of the 4A’s Washington office. O’Brien and other 4A’s staff and members with medical accounts have been meeting with Congressional leaders and key members of the House Ways and Means Committee and the Senate Finance Committee to educate them about the effect such a change would have on consumers and on marketers and media.
For more information about the 4A’s efforts, contact the 4A Washington office, 202-331-7345.
AMA Rejects Ethics Proposal to Limit Industry Collaboration
June 15, 2009 — Today the American Medical Association (AMA) House of Delegates rejected sweeping ethical guidelines against industry collaboration. The guidelines would have suppressed many education and marketing relationships with practicing doctors and medical researchers.
Read more
Results 151-160 of 168
Recent Comments